(Q38375556)

2 September 2017

title

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients (English)

1 reference

2 September 2017

0 references

Toru Mukohara

1

1 reference

2 September 2017

Hikaru Nakajima

2

1 reference

2 September 2017

Hirofumi Mukai

3

1 reference

2 September 2017

Shunji Nagai

4

1 reference

2 September 2017

Kuniaki Itoh

5

1 reference

2 September 2017

Yoshiko Umeyama

6

1 reference

2 September 2017

Junichi Hashimoto

7

1 reference

2 September 2017

Hironobu Minami

8

1 reference

2 September 2017

publication date

9 December 2009

1 reference

2 September 2017

1 reference

2 September 2017

volume

101

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

963-968

1 reference

What Is the Evidence That Tumors Are Angiogenesis Dependent?

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Sunitinib-induced hemoglobin changes are related to the dosing schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01465.X

10.1111/J.1349-7006.2009.01465.X

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference